Prevail Therapeutics to Participate in Fireside Chat at Chardan 4th Annual Genetic Medicines Manufacturing Summit
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology firm specializing in AAV-based gene therapies for neurodegenerative diseases, announced that CEO Asa Abeliovich and CTO Yong Dai will engage in a virtual fireside chat at the Chardan 4th Annual Genetic Medicines Manufacturing Summit on May 26, 2020. The discussion will focus on the company's manufacturing and CMC strategy as well as industry trends. Prevail is developing therapies like PR001 for Parkinson’s disease and PR006 for frontotemporal dementia, showcasing their commitment to innovative treatments.
Details
News Market Reaction – PRVL
The recorded move for PRVL in the trading session of this news was +2.82%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CEO, CTO to Discuss Company’s Manufacturing and CMC Strategy and Overall Industry Trends
NEW YORK, May 21, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer of Prevail, and Yong Dai, Ph.D., Chief Technology Officer of Prevail will participate in a virtual fireside chat at the Chardan 4th Annual Genetic Medicines Manufacturing Summit on Tuesday, May 26, 2020.
About Prevail Therapeutics
Prevail is a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company is developing PR001 for patients with Parkinson’s disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease; PR006 for patients with frontotemporal dementia with GRN mutations (FTD-GRN); and PR004 for patients with certain synucleinopathies.
Prevail was founded by Dr. Asa Abeliovich in 2017, through a collaborative effort with The Silverstein Foundation for Parkinson’s with GBA and OrbiMed, and is headquartered in New York, NY.
Media Contact:
Mary Carmichael
Ten Bridge Communications
mary@tenbridgecommunications.com
617-413-3543
Investor Contact:
investors@prevailtherapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.